Clinical Trial

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Protocol Amendment History 3 changes
notable Trial sites reduced: 53 -> 50 locations 2026-07-21
critical Recruitment opened 2026-04-18
notable Trial sites expanded: 50 -> 53 locations 2026-04-18
Trial Details
NCT Number NCT07218341
Lead Sponsor Eli Lilly and Company
Conditions Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Enrollment 150 participants
Start Date 2026-03-09
Primary Completion 2030-05 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-20